Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study

Authors

  • Gregorio Carretero Dermatology and Venereology Spanish Academy, Madrid - Spain
  • David Moreno Department of Dermatology, Virgen Macarena Hospital, Seville - Spain
  • Almudena González Domínguez Max Weber Institute, Madrid - Spain
  • David Trigos Acción Psoriasis, Psoriasis Patients and Relatives Association, Barcelona - Spain
  • Albert Ledesma Generalitat de Catalunya, Barcelona - Spain
  • Esther Sarquella Generalitat de Catalunya, Barcelona - Spain
  • María Merino Max Weber Institute, Madrid - Spain
  • Carles Blanch Novartis Pharmaceuticals, Madrid - Spain
  • SROI Psoriasis Group

DOI:

https://doi.org/10.33393/grhta.2020.2146

Keywords:

health economics, health care utilization, SROI, social impact, psoriasis, resource optimization

Abstract

Introduction: Psoriasis is a chronic disease in which patients feel stigmatization, social rejection, and suffer from low self-esteem. There are still unmet needs that make it necessary to define a new multidisciplinary approach to provide benefits not only to patients and their families but also to the Spanish National Health System (SNHS) and society. The aim was to define a new approach to better address the unmet needs of patients with psoriasis within the SNHS and to measure its impact from a social perspective, that is, in clinical, health care, economic, and social terms.

Methods: Multidisciplinary experts identified, agreed on, and selected several health care interventions that were feasible for implementation in the SNHS. This process was carried out in four different areas: diagnosis, mild psoriasis, moderate psoriasis, and severe psoriasis. To estimate investment and social return, the social return on investment (SROI) method was used.

Results: The new approach to psoriasis management in the SNHS comprised 18 proposals. The investment needed for the implementation of this new approach would amount to €222.77 million and its return to €1,123.11 million. This would yield a SROI ratio of €5.04 for every euro invested. 

Conclusion: The new approach to psoriasis management would yield a positive social return. The results will allow optimal strategic planning adapted to each assistance situation, to achieve a comprehensive and multidisciplinary approach.

Downloads

Download data is not yet available.

References

Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18.

Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014 May-Jun;32(3):343-350.

World Health Organization. Strategic resource allocation. Report of the Programme, Budget and Administration Committee of the Executive Board to the Sixty-seventh World Health Assembly [Internet]. 2014 [cited 2017 Feb 17]. http://apps.who.int/iris/bitstream/handle/10665/152547/A67_9-en.pdf?sequence=1&isAllowed=y Accessed February 17, 2017.

Chren M-M, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004 Mar;9(2):97-100.

Obradors M, Figueras M, Paz S, Comellas M, Lizán L. Costs of psoriasis in Europe. A systematic review of the literature. Value Health. 2014 Nov 1;17(7):A606.

Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep. 2014 Mar;3(1):61-78.

Ferrándiz C, Carrascosa JM, Toro M. Prevalencia de la psoriasis en España en la era de los agentes biológicos. Actas Dermosifiliogr. 2014;105(5):504-509.

Carrascosa J, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II). J Eur Acad Dermatol Venereol. 2006 Aug;20(7):840-845.

Puig L, Bordas X, Carrascosa JM, et al. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr. 2009;100(4):277-286.

Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-407.

Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006 Oct;155(4):729-736.

Moreno-Ramírez, Fonseca E, Herranz P, Ara M. Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión. Actas Dermosifiliogr. 2010;101(10):858-865.

Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010 Sep;24(9):989-1004.

Richards HL, Chong SLP, Mason DL, Griffiths CE. The impact of psoriasis on healthy partners of patients with psoriasis. Br J Dermatol. 2002;147(Suppl 62):40.

Ros S, Puig L, Carrascosa JM. Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. Actas Dermosifiliogr. 2014;105(2):128-134.

Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006 May;154(5):844-849.

Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug;146(8):891-895.

Nicholls J, Lawlor E, Neitzert E, Goodspeed T. A guide to Social Return on Investment [Internet]. UK: The SROI Network. Accounting for Value; 2012. http://www.socialvalueuk.org/app/uploads/2016/03/The%20Guide%20to%20Social%20Return%20on%20Investment%202015.pdf Accessed February 1, 2017.

Instituto Nacional de Estadística. Estadística del Padrón Continuo a 1 de enero de 2015. [Internet]. 2015 [cited 2016 Mar 1]. http://www.ine.es Accessed March 1, 2016.

Instituto Nacional de Estadística. Media anual del índice general de Precios de Consumo. Base 2011 [Internet]. 2016. http://www.ine.es/jaxiT3/Tabla.htm?t=10305&L=0 Accessed February 26, 2017.

CCEMG—EPPI-Centre Cost Converter v.1.4 [Internet]. [cited 2016 Mar 28]. http://eppi.ioe.ac.uk/costconversion/ Accessed February 26, 2017.

Huerta C, Rivero E, Rodríguez LAG. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-1565.

Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016 Sep;107(7):577-590.

Obradors M, Paz S, Comellas M, Lizán L. Carga económica de la psoriasis en Europa. Revisión de la literatura [Internet]. XXXIV edición de las Jornadas de Economía de la Salud; 2015. https://www.outcomes10.com/wp-content/uploads/2015/02/28.pdf Accessed February 25, 2016.

Polistena B, Calzavara-Pinton P, Altomare G, et al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2411-2416.

Maza A, Richard MA, Aubin F, et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol. 2012 Sep;167(3):643-648.

Luelmo J, Gratacós J, Martínez-Losa MM, et al. Experiencia de 4 años de funcionamiento de una unidad multidisciplinar de psoriasis y artritis psoriásica. Reumatol Clin. 2014;10(3):141-146.

Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 May;70(5):871-881. e1-e30.

Batalla A, Suh-Oh HJ, Salgado-Boquete L, Abalde T, de la Torre C. Teledermatología. Capacidad para reducir consultas presenciales según el grupo de enfermedad. Piel (Barc). 2016;31(3):156-163.

Vaño-Galván S, Hidalgo A, Aguayo-Leiva I, et al. Teledermatología diferida: análisis de validez en una serie de 2.000 observaciones. Actas Dermosifiliogr. 2011;102(4):277-283.

Lafuente-Urrez RF, Martin de Aguilera Moro MC. La enfermería: ¿una colaboración necesaria para el control de nuestros pacientes afectos de psoriasis? Actas Dermosifiliogr. 2014;105(3):213-215.

Ruiz Moral R, Peralta Munguia L, Pérula de Torres LÁ, et al. Opiniones y percepciones de los pacientes sobre su participación en la toma de decisiones en las consultas de medicina de familia. Aten Primaria. 2012;44(1):5-12.

Ayala F, Sampogna F, Romano GV, et al. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1623-1632.

Published

2020-07-17

How to Cite

Carretero, G., Moreno, D., González Domínguez, A., Trigos, D., Ledesma, A., Sarquella, E., Merino, M., Blanch, C., & Psoriasis Group, S. (2020). Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. Global and Regional Health Technology Assessment, 7(1), 50–56. https://doi.org/10.33393/grhta.2020.2146

Issue

Section

Original Research Articles

Categories

Received 2020-05-22
Accepted 2020-06-22
Published 2020-07-17

Metrics

Most read articles by the same author(s)